Colon Cancer, Hepatic Metastases, Rectal Cancer
Conditions
Keywords
BEVACIZUMAB (AVASTIN), DEXAMETHASONE, FLOXURIDINE, FLUOROURACIL, IRINOTECAN (CPT-11) CAMPTOSAR, LEUCOVORIN, OXALIPLATIN, Colon, Rectal, 04-086, Adjuvant postoperative chemo for CLM
Brief summary
The purpose of this study is to determine whether the addition of bevacizumab, to hepatic arterial therapy with floxuridine (FUDR) and dexamethasone (Dex) (regional chemotherapy), and either oxaliplatin or CPT-11, plus 5-fluorouracil and leucovorin (systemic chemotherapy) will increase disease free survival in patients who have undergone liver resection. The patient will be randomized (a computer generated decision as in the flip of a coin) to receive, or not to receive bevacizumab in addition to regional and systemic chemotherapy.
Interventions
DRUGBevacizumab HAI plus systemic chemotherapy
Oxaliplatin (mg/m2) IV, over 2 hours, 5 FU (mg/m2) continuous infusion, over two days, leucovorin (mg/m2) IV, over 2 hours
DRUGHAI plus systemic chemotherapy
Irinotecan (mg/m2) IV, over 30 minutes, 5 FU (mg/m2) continuous infusion over two days, leucovorin (mg/m2) IV, over 30 minutes
Sponsors
Memorial Sloan Kettering Cancer Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* History of histologically confirmed colorectal adenocarcinoma metastatic to the liver with no clinical or radiographic evidence of extrahepatic disease. Confirmation of diagnosis must be performed at MSKCC. * Potentially completely resectable hepatic metastases without current evidence of other metastatic disease. * Abdominal and pelvic CT scans and chest CT or x-ray within 6 weeks prior to registration. (MRI of abdomen may be substituted for CT of abdomen.) * Lab values within 14 days prior to registration: * WBC ≥ 3.0 K/uL * ANC \> 1.5 K/uL * Platelets ≥ 75 K/uL * Total bilirubin \< 1.5 mg/dL * INR \< 1.5 * Creatinine \< 2.0 mg/dL * HGB ≥ 9 gm/dL * Prior chemotherapy is acceptable if last dose given ≥ 3 weeks prior to registration to this study. \[Note: no chemotherapy to be given after resection of liver lesions prior to treatment on this study.\] * KPS ≥ 70% * Signed informed consent * Patient age must be \>18
Exclusion criteria
* Prior radiation to the liver. (Prior radiation therapy to the pelvis is acceptable if completed at least 4 weeks prior to registration.) * Active infection, ascites, hepatic encephalopathy. * Prior treatment with HAI FUDR. * Female patients who are pregnant or lactating. * Subjects discovered to have ≥1+ proteinuria at baseline will undergo a 24-hour urine collection, which must be an adequate collection and must demonstrate \<1 g of protein/24 hours to allow participation in this study. * Patients may not be receiving any other investigational agents * Patients with known brain metastases that would confound the evaluation of neurologic and other adverse events will be excluded. Patients with history of primary CNS tumors, seizures not well-controlled with standard medical therapy, or history of stroke will also be excluded. * History of allergic reactions attributed to compounds of similar chemical or biologic composition to bevacizumab. * Serious or non-healing active wound, ulcer, or bone fracture * Major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to Day 1 of protocol treatment. (Surgery performed to resect metastatic lesions and place pump will not exclude patient from protocol; Day 1 of protocol treatment will take place no sooner than 28 days after surgery.) * Current or recent use of a thrombolytic agent. * Chronic daily treatment with aspirin (\> 325 mg/d) or nonsteroidal anti-inflammatory medications known to inhibit the platelet function. * Presence of bleeding diathesis or coagulopathy. * History of serious systemic disease, including myocardial infarction within the last 12 months, uncontrolled hypertension (blood pressure of \> 160/110 mmHg on medication), unstable angina within the last 12 months, New York Heart Association (NYHA) Grade II or greater congestive heart failure (see Appendix C), unstable symptomatic arrhythmia requiring medication (subjects with chronic atrial arrhythmia, i. e. atrial fibrillation or paroxysmal supraventricular tachycardia are eligible), or peripheral vascular disease (Grade II or greater). * Patients with a history of stroke or transient ischemic attack. * Presence of central nervous system or brain metastases. * Patients who have a diagnosis of Gilbert's disease.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To determine whether the addition of concurrent intravenous bevacizumab to HAI plus systemic chemotherapy increases the time to progression in patients with completely resected hepatic metastases from colorectal cancer | 7.5 months |
Secondary
| Measure | Time frame |
|---|---|
| To assess toxicity | 7.5 months |
| To determine survival | 2 years |
| To assess the expression pattern of VEGFR1, VEGFR2 (angiogenesis), and VEGFR3 (lymphangiogenesis) and their cognate ligands (VEGF-A, VEGF-C, VEGF-D), and correlate with patient progression and survival following | 2 years |
| To compare plasma levels of VEGF-A, VEGF-C, VEGF-D, and CD133+ VEGFR2+ circulating endothelial progenitors | 2 years |
Countries
United States
Outcome results
None listed